4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Denali Therapeutics Inc. (DNLI) operates in the Biotechnology industry and is headquartered in South San Francisco, United States with about 507 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, DNLI reported $0M in revenue and ($512M) in net income.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $330M | $108M | — |
| Operating Income (EBIT) | ($555M) | ($502M) | ($197M) | ($341M) | — |
| Net Income | ($512M) | ($423M) | ($145M) | ($326M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($137M) | ($137M) | ($137M) | ($135M) | ($146M) | — |
| Net Income | ($128M) | ($128M) | ($127M) | ($124M) | ($133M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.1B | $1.4B | $1.2B | $1.5B | — |
| Total Liabilities | $131M | $144M | $123M | $418M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DNLI viewer.
About TickerBase · Data methodology & sources